BUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨

路透中文

Feb 03

BUZZ-Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 因血癌药物早期试验获得 FDA 批准而上涨

2月3日 - ** 药物开发商 Prelude Therapeutics PRLD.O 股价盘前上涨 6.85% 至 2.13 美元

** 该公司称 (link)，美国FDA已批准对其实验性药物PRT12396进行人体试验，该药物可用于治疗多发性红细胞症和骨髓纤维化--人体制造过多异常血细胞的血癌。

** PRLD表示，这项早期研究将评估安全性和高风险患者的初步获益迹象

** PRT12396旨在针对这两种疾病中常见的基因突变 - PRLD

** 公司预计将于2026年第二季度开始招募患者，并表示已与Incyte INCY.O就该项目达成独家选择权协议

** 2025年股价上涨了一倍多

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608187739"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608187739\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608187739?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-03 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608187739","market":"hk","top_or_hot":-1,"title":"BUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 因血癌药物早期试验获得 FDA 批准而上涨</title></head><body><p><span>2月3日</span><span> - </span>** 药物开发商 Prelude Therapeutics <span>PRLD.O</span> 股价盘前上涨 6.85% 至 2.13 美元 </p><p>** 该公司称 (link)，美国FDA已批准对其实验性药物PRT12396进行人体试验，该药物可用于治疗多发性红细胞症和骨髓纤维化--人体制造过多异常血细胞的血癌。</p><p>** PRLD表示，这项早期研究将评估安全性和高风险患者的初步获益迹象</p><p>** PRT12396旨在针对这两种疾病中常见的基因突变 - PRLD</p><p>** 公司预计将于2026年第二季度开始招募患者，并表示已与Incyte <span>INCY.O</span>就该项目达成独家选择权协议 </p><p>** 2025年股价上涨了一倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-02-03 22:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 因血癌药物早期试验获得 FDA 批准而上涨</title></head><body><p><span>2月3日</span><span> - </span>** 药物开发商 Prelude Therapeutics <span>PRLD.O</span> 股价盘前上涨 6.85% 至 2.13 美元 </p><p>** 该公司称 (link)，美国FDA已批准对其实验性药物PRT12396进行人体试验，该药物可用于治疗多发性红细胞症和骨髓纤维化--人体制造过多异常血细胞的血癌。</p><p>** PRLD表示，这项早期研究将评估安全性和高风险患者的初步获益迹象</p><p>** PRT12396旨在针对这两种疾病中常见的基因突变 - PRLD</p><p>** 公司预计将于2026年第二季度开始招募患者，并表示已与Incyte <span>INCY.O</span>就该项目达成独家选择权协议 </p><p>** 2025年股价上涨了一倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRLD","symbol_name":"Prelude Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4T3YZ1H2:1","article_id":"2608187739","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608187739","pubTimestamp":1770128996,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨2月3日 - ** 药物开发商 Prelude Therapeutics PRLD.O 股价盘前上涨 6.85% 至 2.13 美元 ** 该公司称 ，美国FDA已批准对其实验性药物PRT12396进行人体试验，该药物可用于治疗多发性红细胞症和骨髓纤维化--人体制造过多异常血细胞的血癌。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PRLD":"Prelude Therapeutics Inc","BK4550":"红杉资本持仓","BK4588":"碎股","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"BUZZ-Prelude Therapeutics Rises on FDA Approval for Early Trial of Blood Cancer Drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRLD":0.9,"INCY":0.9},"content_text":"BUZZ-Prelude Therapeutics 因血癌药物早期试验获得 FDA 批准而上涨2月3日 - ** 药物开发商 Prelude Therapeutics PRLD.O 股价盘前上涨 6.85% 至 2.13 美元 ** 该公司称 (link)，美国FDA已批准对其实验性药物PRT12396进行人体试验，该药物可用于治疗多发性红细胞症和骨髓纤维化--人体制造过多异常血细胞的血癌。** PRLD表示，这项早期研究将评估安全性和高风险患者的初步获益迹象** PRT12396旨在针对这两种疾病中常见的基因突变 - PRLD** 公司预计将于2026年第二季度开始招募患者，并表示已与Incyte INCY.O就该项目达成独家选择权协议 ** 2025年股价上涨了一倍多(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}